Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

por Patnaik, A, Weiss, G J, Papadopoulos, K P, Hofmeister, C C, Tibes, R, Tolcher, A, Isaacs, R, Jac, J, Han, M, Payumo, F C, Cotreau, M M, Ramanathan, R K
Publicado 2014

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

por Richardson, P G, Hofmeister, C C, Raje, N S, Siegel, D S, Lonial, S, Laubach, J, Efebera, Y A, Vesole, D H, Nooka, A K, Rosenblatt, J, Doss, D, Zaki, M H, Bensmaine, A, Herring, J, Li, Y, Watkins, L, Chen, M S, Anderson, K C
Publicado 2017

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

por Richardson, P. G., Hofmeister, C. C., Raje, N. S., Siegel, D. S., Lonial, S., Laubach, J., Efebera, Y. A., Vesole, D. H., Nooka, A. K., Rosenblatt, J., Doss, D., Zaki, M. H., Bensmaine, A., Herring, J., Li, Y., Watkins, L., Chen, M. S., Anderson, K. C.
Publicado 2018